Because of controllable liver dysfunction in HCC patients and regular supervision of transaminase indicators, few patients suffered immune-mediated hepatitis and no HBV or HCV viral flares were observed in patients receiving anti-PD-1/PDL1 therapy (57, 60). This evidence concerns the gene PDCD1 and hepatocellular carcinoma.